Skip to navigation Skip to content

About MS

MS overview, disease courses, epidemiology and theories of causation

Diagnosis & Management Healthcare Professional App

Download this unique, FREE tool and resource that provides important information about the diagnosis and management of multiple sclerosis for practicing clinicians. The App is a concise compilation of current, easy-to-reference, evidence-based information that you can access at no charge as an Apple and Droid "App".

App production made possible by Allergan, Bayer HealthCare, Novartis and Questcor Pharmaceuticals, Inc.

Download for iPhone

Download for Android

Share

Overview

Multiple sclerosis (MS) is a chronic, inflammatory disease of unknown etiology that involves an immune-mediated attack on the central nervous system. Myelin and the oligodendrocytes that form myelin appear to be the primary targets of the inflammatory attack, although the axons themselves are also damaged. The inflammatory attack on CNS white matter is associated with T lymphocyte activity (Th-1 and Th-17), impairment of regulatory T cell function and B lymphocyte activity (antibody and complement). Gray and white matter are targeted by the abnormal immune response. The collective damage to white and gray matter results in a broad spectrum of clinical signs and symptoms.

The disease is thought to be precipitated by a combination of one or more environmental triggers acting in a genetically susceptible individual.

In approximately 85 percent of patients, MS begins with a relapsing-remitting course (RRMS). In a much smaller percentage of patients, the disease is progressive from onset (primary-progressive MS). Most people with RRMS have fewer relapses and less inflammatory activity over time, eventually transitioning to a more progressive course -- secondary-progressive MS (SPMS). The onset of SPMS appears to be a dominant determinant of long-term disease prognosis (Scalfari et al., 2014). Male sex, older age at disease onset, and a higher number of early relapses are associated with a higher probability of progressive disease and shorter time to SPMS (Scalfari et al., 2014, Alroughani et al., 2015). A prediction model based on age, cortical lesion load, and cerebellar cortical volume has been offered to explain the probability of evolving to SPMS (Calabrese et al., 2013). There is growing evidence that gray matter damage plays a pivotal role in MS disease progression (Calabrese et al., 2013, Herranz et al., 2016, Lavorgna et al, 2014 & Tortorella, 2014). Preventing the onset of SPMS is a primary target of treatment at this time (Scalfari et al., 2013).

Share


Become a Research Champion

An MS Research Revolution

Support MS Research

Understanding and ending MS can’t come fast enough – it will take all of us working together. It’s easy to be a champion for MS Research – join us and proudly let everyone know that you’re helping to lead the MS Research Revolution.

Become a Research Champion

Become a Research Champion